Sergio Pérez

Vivia Biotech SL provides biotechnology research services and laboratory instruments. It is a research and development company that focuses on the drug effects on hematological cancer patients. The firm provides personalized medicine test for blood cancers that can help predict the patient's response to treatment prior to its administration. The company was founded by Juan Antonio Ballesteros Nobell, Andrés Ballesteros Nobell and Fernando Rodríguez de Fonseca in September 2007 and is headquartered in Tres Cantos, Spain.

Chemo Ibérica SA develops and distributes pharmaceutical products. It also produces veterinery finished products, raw materials, intermediate products from synthesis and other fine chemicals. Its activities are grouped under chemistry, generics, healthcare, veterinery and agrochemicals. The company also operates in India, China, Italy, Guatemala, Switzerland, Hungary, Argentina, Belgium & Luxembourg through subsidiaries, joint ventures and commercial offices. Chemo Iberica was founded in 1977 and is headquartered in Madrid, Spain.

Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.